Sandra Shotwell

Dr. Sandra Shotwell is an experienced biotech entrepreneur, with a passion for global health.  She is cofounder and CEO of DesignMedix Inc and cofounder and board chair for Elex Biotech Inc, companies that develop small molecule therapeutics for infectious disease and heart disease, respectively. DesignMedix’s lead drug candidate designed to overcome drug resistance in malaria is in Phase I clinical trails at Duke Clinical Research Institute, sponsored by the NIH National Institute of Allergy and Infectious Disease.